Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants

To compare the pharmacokinetics (PK), safety, tolerability, and immunogenicity of single intravenous doses of FKB238, a proposed biosimilar of bevacizumab, with European Union (EU)-approved and United States (US)-licensed bevacizumab in healthy participants. In a randomized, double-blind, parallel-g...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of clinical pharmacology and therapeutics 2022-06, Vol.60 (6), p.280-290
Hauptverfasser:	Boyce, Malcolm, Wilkes, Denisa, Kaito, Hidekuni, Takanuma, Masayuki, Arai, Yasumasa
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological products Pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!